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Background: Numerous efforts have been made to elucidate the etiology and improve the treatment of lung
cancer, but the overall five-year survival rate is still only 15%. Although cigarette smoking is the primary risk factor for
lung cancer, only 7% of female lung cancer patients in Taiwan have a history of smoking. Since cancer results from
progressive accumulation of genetic aberrations, genomic rearrangements may be early events in carcinogenesis.
Results: In order to identify biomarkers of early-stage adenocarcinoma, the genome-wide DNA aberrations of 60 pairs
of lung adenocarcinoma and adjacent normal lung tissue in non-smoking women were examined using Affymetrix
Genome-Wide Human SNP 6.0 arrays. Common copy number variation (CNV) regions were identified by ≥30% of
patients with copy number beyond 2 ± 0.5 of copy numbers for each single nucleotide polymorphism (SNP) and at
least 100 continuous SNP variant loci. SNPs associated with lung adenocarcinoma were identified by McNemar’s test.
Loss of heterozygosity (LOH) SNPs were identified in ≥18% of patients with LOH in the locus. Aberration of SNP
rs10248565 at HDAC9 in chromosome 7p21.1 was identified from concurrent analyses of CNVs, SNPs, and LOH.
Conclusion: The results elucidate the genetic etiology of lung adenocarcinoma by demonstrating that SNP rs10248565
may be a potential biomarker of cancer susceptibility.
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One of most commonly diagnosed cancers is lung cancer,
which accounts for nearly 18% of all cancer-related deaths
worldwide [1]. In the United States and other Western
countries, the 5-year survival rate of lung cancer is only
15% and has not improved over several decades. In
Taiwan, lung cancer mortality rates have become the high-
est in the world [2,3]. Even though numerous research ef-
forts have been devoted to the development of lung
cancer treatment over the past few decades, the overall 5-
year survival rate is still as low as 15% [4].
Smoking is the primary risk factor for lung cancer [5].
In Western countries, 70-90% of lung cancers are attrib-
utable to cigarette smoking, whereas in Taiwan, only 7%* Correspondence: llai@ntu.edu.tw; chuangey@ntu.edu.tw
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[6,7]. Most non-smoking female patients with lung can-
cer have adenocarcinoma. However, the molecular
mechanisms of lung adenocarcinoma in non-smoking
women remain unclear.
Cancer appears to result from the progressive accumula-
tion of genetic aberrations ranging from large, visible
chromosome events to single nucleotide polymorphisms
(SNPs). Genomic rearrangements that affect DNA se-
quences are called structural variants and include such
things as insertions, deletions, duplications and inversions
[8]. When the length of a structural variant is 1 kb or lon-
ger, it is defined as a copy number variation (CNV). CNVs
have played important roles in recent cancer studies. Du-
plicated chromosomal regions may contain dominant on-
cogenes (e.g., MYC and ERBB2 [9-11]), whereas deleted
regions may harbor tumor suppressor genes (e.g., RB1,
CDKN2A, and PTEN [9-15]). These genes play criticalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation, apoptosis, and metastasis. For example, genomic
imbalances and losses at 16q were shown to be associated
with more poorly differentiated subtypes of prostate
cancer [16]. DNA CNVs explained about 12% of the
gene expression variations in breast cancer [17]. Concord-
ant changes between mRNA expression levels and CNVs
were observed in several genes located in copy number
variable regions in lung cancer [18,19]. Furthermore, gene
CNVs have been shown to be useful in predicting patient
survival outcomes in lung cancer [20,21]. For example, the
amplification and overexpression of epidermal growth fac-
tor receptor (EGFR) and the under-expression of dual spe-
cificity phosphates 4 (DUSP4) served as effective prognostic
biomarkers in lung cancer [19,22]. Therefore, it is import-
ant to characterize DNA copy number changes for both the
basic understanding of cancer and its diagnosis.
In this study, the genomic aberrations of lung adenocar-
cinoma in non-smoking women were examined using
genome-wide human SNP arrays. The primary advantage
of SNP arrays for our purposes was that the probe inten-
sity of both alleles at each SNP allows the detection of
CNV breakpoints and the estimation of the associated
number of copies. In addition, loss of heterozygosity
(LOH), used for surveying segments of allelic losses, can
be examined by analyzing the genotype of both normal
and lung tissues [23,24].
Although SNP genotyping is often used for examining
the associations between cancer and normal tissues, the
main focus of this study was not to identify the association
of SNPs with lung adenocarcinoma in non-smoking
women. Instead, we took advantage of the ability of whole-
genome SNP arrays to concurrently analyze CNVs, SNPs,
and LOH in order to identify the novel focal loci of lung
adenocarcinoma. All results indicated that the SNP
rs10248565 in HDAC9, the gene encoding histone deacety-
lase, was related to lung carcinogenesis. In this study, we
demonstrated that SNP rs10248565 in HDAC9 may be a
potential biomarker for identifying important genetic de-
terminants of cancer susceptibility and elucidating the gen-
etic etiology of lung cancer in non-smoking females.
Methods
Sample collection
The study protocol was approved by the institutional re-
view boards of National Taiwan University Hospital and
Taichung Veterans General Hospital. The written con-
sent form was approved by ethics committees, and all
participants agreed with their written consents to participate
in this study. In total, 120 pairs of cancer and normal lung
tissue specimens were collected from non-smoking females.
The selection criteria of clinical specimens depended on the
pathology report, physical examination and cigarette smok-
ing history. Surgical lung tissue specimens were immediatelysnap-frozen in liquid N2 and stored at −80°C until be-
ing further processed for DNA extraction. Only those
paired samples passing quality checks (n = 61 pairs)
were processed for SNP arrays.
Isolation of genomic DNA, DNA amplification, labeling
and hybridization of SNP arrays
Genomic DNA was isolated by phenol/chloroform extrac-
tion following standard protocols with 0.5% SDS and
200 μg/ml proteinase K. Total genomic DNA (250 ng)
was digested with a restriction enzyme (NspI or StyI) and
ligated to adaptors that recognize the cohesive four bp
overhangs. All fragments resulting from restriction en-
zyme digestion were substrates for adaptor ligation. A
generic primer that recognizes the adaptor sequence was
used to amplify adaptor-ligated DNA fragments. PCR con-
ditions had been optimized to preferentially amplify frag-
ments in the 200 to 1,100 bp size range. The amplified
DNA was then fragmented, labeled, and hybridized to
Genome-Wide Human SNP 6.0 arrays (Affymetrix, Inc.,
Santa Clara, CA). After 16 hours of hybridization at 49°C,
the arrays were washed by Fluidics Station 450 and
scanned by GeneChip Scanner 3000. Microarray data of
this study are MIAME compliant, and have been submit-
ted to the MIAME compliant Gene Expression Omnibus
(GEO) database (accession number GSE33355).
Copy number variation analysis
After scanning, the intensity data were analyzed by Partek®
software (Partek®, St. Louis, MO, USA). Since both tumor
and adjacent normal tissues were from the same individ-
ual, the reference baseline for each tumor tissue was its
corresponding normal tissue. The criteria for searching
for CNV regions in the whole genome were as follows: 1)
copy number intensity ratio of tumor to normal tissue for
each SNP was >2.5 or <1.5; 2) each individual had ≥100
continuous SNP variant loci; 3) the CNV regions existed
in ≥30% of the study population. The overlapping genes
located within the detected CNV regions were annotated
using the documentation file version 30 provided by
Affymetrix.
TaqMan® copy number assays
TaqMan® assays were used to validate the total copy
number of CNV regions. Total genomic DNA (20 ng;
5 ng/μl) was used for TaqMan® Copy Number assays
(Life Technologies, Carlsbad, CA, USA). All reactions
were performed in duplicate, including the FAM™ dye
label-based assay for the target of interest and the VIC®
dye label-based TaqMan® Copy Number Reference Assay.
The TaqMan® probes for the target of interest were labeled
with FAM at the 5′ end and linked by a non-fluorescent
quencher at the 3′ end. RNase P labeled with VIC dye
(Life Technologies) was utilized as the reference gene,
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All TaqMan® assays were performed following manufac-
turer’s instructions and copy number calculation was con-
ducted by the delta-delta threshold cycle (ΔΔCt) method.
PCR was performed with an Applied Biosystems 7900HT
Fast Real-Time PCR System (Applied Biosystems, Carls-
bad, CA, USA). Results were analyzed by CopyCaller™ ver-
sion 1.0. Tumor samples with a delta Ct value between
target and reference sequences were measured, and then
compared to their paired normal samples.
Single nucleotide polymorphism analysis
For SNP analysis, SNPs were obtained using Affymetrix®
SNP Array 6.0 (each has more than 906,600 SNPs). After
excluding SNPs with allele frequency <1% (157,703
SNPs) or call rate <90% (123 SNPs), 748,774 SNPs were
further analyzed by McNemar-Bowker’s test to examine
the difference of genotypes between normal and tumor
tissues from the same subject. SNPs were coded according
to the number of minor alleles, i.e., AA, Aa and aa, deno
ted as 0, 1, 2, respectively. The nonparametric McNemar-
Bowker’s test was applied to examine the association
between SNPs and tissues. The analyses were done in R
version 2.9.0.
Loss of heterozygosity analysis
Loss of heterozygosity (LOH) was defined as heterozygos-
ity in normal tissue and homozygosity in tumor tissue.
The genotypes between tumor tissue and its normal coun-
terpart from the same subject were compared using
Genome-Wide Human SNP 6.0 arrays (Affymetrix, Inc.,
Santa Clara, CA). LOH SNPs were identified in ≥18% of
patients with LOH in the locus.
Results
DNA genetic aberration analysis
In this study, pairs of adenocarcinoma and adjacent nor-
mal lung tissue specimens were collected from 61 non-
smoking women for the purpose of examining genome-
wide DNA aberrations. The majority (72%; n = 44) of
women were in early stages (I + II) and the mean (SD) age
was 59.4 (11). Their clinical characteristics are listed in
Table 1. CNV, SNP, and LOH were concurrently analyzedTable 1 Characteristics of 61 non-smoking female lung
adenocarcinoma patients
Characteristics Sample size Age
Female 61 59.4 ± 11
Tumor types
Adenocarcinoma 61 59.4 ± 11
Tumor stage
I + II 44 60 ± 11
III + IV 17 58 ± 11using Affymetrix Genome-Wide Human SNP 6.0 arrays.
All chips’ call rates were greater than 99%.
Copy number variation analysis
We first identified common CNV regions among these
lung adenocarcinoma samples. The criteria for searching
the CNV regions in whole genome were stated in the
Methods section. In total, there were 424 CNV regions.
Figure 1A shows the distribution of CNV for each
chromosome among 61 paired samples. Each grey bar in-
dicates the amplification or deletion regions in tumor tis-
sue. Black bars indicate where >30% of patients (n > 18)
had CNV. An expanded view of these results showed that
one third or more of these patients had a genetic amplifi-
cation at 7p21.3-7p21.1 and 7p11.2 (Figure 1B). In con-
trast, no common deletion regions were identified.
In order to validate the common amplification regions,
four CNV regions in 7p21.1 were chosen for TaqMan®
copy number assays. In the upper panel of Figure 1C,
the positions of 4 CNV regions (black blocks) identified
by SNP arrays and those examined by TaqMan® copy
number assays (grey blocks) are shown. The TaqMan as-
says showed that the copy numbers in all 4 regions were
greater than normal (lower panel of Figure 1C), indicat-
ing these regions are common amplification regions in
non-smoking female lung cancer patients.
In order to understand the function of genes in com-
mon amplification regions, functional analysis was done
using Ingenuity Pathway Analysis (IPA). The results re-
vealed that the common amplification regions contain 29
genes. Network analysis showed that these genes were
mainly involved in cellular development, cellular growth
and proliferation, and cancer. Among these 29 genes,
EGFR (encoding epidermal growth factor receptor) and
HDAC9 were previously reported to have an association
with lung tumorigenesis.
Single nucleotide polymorphism analysis
Next, genotyping of SNPs was analyzed in normal and
adenocarcinoma tissues from the same subject. SNPs with
minor allele frequency <0.01 were excluded. After exclud-
ing SNPs with low minor allele frequency (181,503 SNPs)
or SNPs with departing Hardy-Weinberg Equilibrium
(P-value <0.0001; 2,816 SNPs), the remaining 684,877
SNPs on autosomal chromosomes were further ana-
lyzed by McNemar-Bowker’s test to examine the differ-
ences in genotypes.
Since this study adopted a paired design, which pro-
vides less variation than general case–control studies
and can achieve a higher statistical power, a strict cri-
terion of P-values, Bonferroni correction, was not per-
formed. As shown in Figure 2, a Manhattan plot
showed that there were four SNPs with P-values
smaller than 0.01. Each dot represents a SNP. The
Figure 1 (See legend on next page.)
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Figure 1 Copy number variation analysis in non-smoking female lung adenocarcinoma patients. (A) Distribution of genome-wide CNV using
Affymetrix GeneChip® SNP 6.0 analysis. The criteria for the CNV regions were that SNPs must have copy numbers >2.5 or <1.5 and there must be at
least 100 continuous SNP variant loci. Grey bars indicate regions with gains (above) or losses (below) in copy number. Black bars indicate that ≥30% of
the patients had a particular CNV. (B) Common gain regions (≥30% of patients) of CNVs (grey area) were identified in 7p21.3-7p21.1 and 7p11.2. Black
lines of each row indicate regions with copy number amplifications at >100 continuous SNP loci for each patient. (C) TaqMan assay validation of CNVs
in chromosome 7p21.1. Four CNV regions (black block 1–4) identified by SNP arrays were examined using TaqMan® copy number assays (grey block).
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across chromosomes. Information on these four SNPs
(rs1700874, rs10248565, rs11761619, and rs9316119) is
listed in Table 2. Only rs1700874 was located in an
intergenic region (between TGFB2 and LYPLAL1); the
rest of the SNPs were located in introns. Among them,
the SNP with the lowest P-value, rs10248565, is located
in an intron of HDAC9.
Loss of heterozygosity analysis
Lastly, we examined the distribution of LOH in each
chromosome (Figure 3). Because the proportion of LOH
loci ranged from 10% to over 50%, LOH for a SNP was
defined as at least 18% of patients (≥11 patients) with
LOH in the locus. As shown in Figure 3A, black bars in-
dicate ≥18% of patients with the LOH SNP. In total,
there were 30 SNPs indicating LOH. Most of these SNPs
appeared in chromosome 7 (Figure 3B).
Among these LOH SNPs, we noticed that SNP
rs10248565 was associated with lung adenocarcinoma and
was located in the CNV region. Combining the results of
CNV, SNP, and LOH analyses (Figure 4), we concluded
that rs10248565 is a possible biomarker of lung adenocar-
cinoma in non-smoking females.
Discussion
It is well-known that there are many causative elements in
cancer progression and tumorigenesis, such as se-
quence mutations, transcriptional alterations, and gen-
omic changes. Among these complicated factors,Figure 2 Single nucleotide polymorphism analysis in non-smoking fe
distribution of –log(P-value) of each SNP was plotted across chromosomesstructural variations of DNA sequences have been
widely reported to serve as a key driver to dysregulate
the transcriptome during tumorigenesis [17]. Further-
more, since genes located within the variable regions
are candidate oncogenes or tumor suppressors, an inte-
grative analysis of CNV, SNP, and LOH may provide
more information in dissecting the lung tumorigenic
process. To help explain the relationship between copy
number and gene expression, we performed an integra-
tive analysis in paired lung adenocarcinoma tissue spec-
imens to identify genomic alterations in tumor tissues.
Our CNV results showed that at least 30% of the sam-
ples had amplifications at chromosomes 7p21.3-7p21.1
and 7p11.2. However, no deletion regions were identified.
This may due to the stringent selection criteria adopted
here. Comparing with other studies, several aberrant re-
gions have been detected using high resolution karyotyp-
ing techniques to scan lung cancer genome, such as
amplifications of 3p25-27 and 5p13-14, and deletions of
3p21 and 9q21 [25]. Several studies reported that a dele-
tion on chromosome 5q in small cell and squamous cell
lung cancer subtypes may be associated with smoking his-
tory [26-29]. Conversely, amplifications of 5q have been
detected in adenocarcinoma [30,31]. We did not observe
any amplification regions in chromosome 5 in this study,
which may be explained by differences in experimental de-
sign, selection criteria, and ethnicity of study populations.
Further investigations of the 29 genes located within
these CNV regions identified several key players in-
volved in the tumorigenic process. For instance, loss ofmale lung adenocarcinoma patients. Each dot denotes a SNP. The
. The four SNPs with P-values smaller than 10−2 are labeled.
Table 2 SNPs significantly associated with lung tumors in
non-smoking female patients
SNP Chromosome Position P-value Location
rs1700874 1 219,182,858 4 × 10−3 Intergenic TGFB2
& LYPLAL1
rs10248565 7 18,974,723 3 × 10−3 HDAC9 intron
rs11761619 7 33,549,392 8 × 10−3 BBS9 intron
rs9316119 13 45,696,862 6 × 10−3 GTF2F2 intron
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loviral IAP repeat-containing 2/3 (BIRC2/3) can facilitate
lung cancer cell proliferation and contribute to lung
tumor development [32,33]. EGFR is involved in the signal
transduction pathways of cell proliferation, differentiation,
adhesion, protection from apoptosis and survival. Numer-
ous reports have shown that EGFR gene mutations are
frequently detected in lung cancer, especially in adenocar-
cinoma, females, and non-smoking patients [34].
The gene encoding HDAC in chromosome 7p21.1 was
identified in all CNV, SNP and LOH analyses and is
worthy of mention here. HDAC is involved in deacetyla-
tion of lysine residues in the N-terminal tails of nucleo-
somal core histones [35], and it has also been implicated
in the development of cancer [36]. The activity of several
tumor suppressors is regulated in part by HDACs, such as
p53 binding protein that regulates cell cycling in response
to DNA damage [37]. HDAC inhibitors were developed as
anti-cancer agents with a high degree of selectivity for kill-
ing cancer cells. In one study, inhibition of HDAC induced
DNA damage which only normal cells, but not cancer
cells, can repair, and resulted in cancer cell death [38].Figure 3 Loss of heterozygosity analysis in non-smoking female lung
GeneChip® SNP 6.0 analysis. Grey bars indicate regions with LOH SNPs. Blac
LOH SNP. (B) Frequency of LOH SNPs in each chromosome.Inhibition of HDAC6 significantly enhanced cell death in-
duced by the topoisomerase II inhibitors in transformed
cells, but not in normal cells [21]. Inhibition of HDAC1
and HDAC2 enhanced the radiosensitivity of non-small
cell lung cancer [39]. Unfortunately, the expression levels
of HDAC9 did not differ significantly between tumor tis-
sue and adjacent normal tissue in our study (data not
shown). This may be due to the location of the SNP in an
intron of HDAC9, and further investigation of the mech-
anism of genomic aberration in HDAC9 is warranted.
The hypothesis underlying our SNP analysis was that if
SNPs were associated with cancer, the proportions of dif-
ferent alleles would be different in cancer and normal
groups. Previously, rs7086803 at 10q25.2, rs9387478 at
6q22.2 and rs2395185 at 6p21.32 were identified as lung
cancer susceptibility loci in never-smoking women in Asia
[40]. In this study, we identified another 4 SNPs (rs170
0874, rs10248565, rs11761619, and rs9316119) that were
significantly (P <0.01) associated with lung cancer. SNP
rs1700874 is located at an intergenic region in 1q41 be-
tween TGFB2 and LYPLAL1. The transforming growth
factor beta family plays an important role in cell cycling,
cell growth, apoptosis, and protein synthesis, and is there-
fore involved in many pathological processes [41,42]. A
previous study showed that TGFB2 may correlate with
heart disease and pulmonary function in mice [43]. The
function of LYPLAL1 is still unclear. SNP rs10248565 is lo-
cated in 7p21.1 within HDAC9, the significance of which
was discussed above. SNP rs11761619 is in 7p14.3 within
BBS9. BBS9 is associated with kidney and ovarian diseases
[44,45], and may be a tumor suppressor gene for Wilms’
tumor [46]. SNP rs9316119 is in 13q14.12 within GTF2F2,adenocarcinoma patients. (A) Distribution of LOH using Affymetrix
k bars indicate that >18% of total patients (n > 11) had a particular
Figure 4 Genomic aberration of SNP rs10248565 was identified using (A) CNV, (B) SNP, and (C) LOH analyses. In each panel, SNP rs10248565
is indicated by a black bar.
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epithelial ovarian cancer [47].
In this study, we identified 30 SNPs with LOH. Most
of these LOH SNPs were located in chromosome 7
(Figure 3B). LOH analysis has been used to identify
genomic aberrations in previous studies. For instance,
loss of heterozygosity at chromosomal regions 3p21.3
(site of RASSF1A, a member of the Ras association do-
main family, and FUS1), 3p14.2 (FHIT, a fragile histi-
dine triad gene), 9p21 (p16), and 17p13 (p53) was
identified as an early event in the development of non-
small cell lung cancer [48].
It may seem contradictory that the SNP rs10248565
in HDAC9 was increased in copy number but also
showed loss of heterozygosity. The observed LOH ac-
companied by a gain in copy number may result from
preferential amplification of one parental allele, because
CNV analysis cannot identify situations in which the
loss of one allele is followed by duplication of the
remaining allele. Also, LOH cannot detect any amplifi-
cation that might be involved in pathogenesis. There-
fore, we conducted a concurrent LOH and CNVanalysis with the expectation of more precisely defining
the nature of genomic alternations observed in either
analysis alone.Conclusion
In conclusion, the high mortality of lung cancer world-
wide is largely attributable to the difficulty of obtaining
an early diagnosis and the lack of effective therapeutic
methods. To improve survival rates in non-smoking
lung cancer patients, a comprehensive analysis of the
molecular signature of the carcinogenic processes in
adenocarcinoma in non-smoking Taiwanese women
was conducted to identify novel biomarkers for diagno-
sis and new molecular targets for drug development.
Although more studies are still needed, SNP
rs10248565 in HDAC9 may be one of the potential bio-
markers for lung adenocarcinoma in non-smoking
women.
Microarray data from this study have been submitted
to the Gene Expression Omnibus database (accession
number GSE33355).
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